CellType

CellType
Agentic drug company using a 27B biological foundation model to simulate human cellular responses to drugs.
About
What does CellType do?
CellType is an agentic drug discovery company that leverages a 27 billion parameter biological foundation model to simulate human cellular responses to drugs. By replacing traditional micrographs and wet-lab cycles with advanced computational biology, CellType aims to accelerate and de-risk the drug development process.
Where is CellType headquartered?
CellType is headquartered in San Francisco, United States.
When was CellType founded?
CellType was founded in 2023.
What industry does CellType operate in?
CellType operates in Biotech, Drug Discovery, Computational Biology, Foundation Model, Agentic AI, AI-Driven Drug Discovery.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Leading AI agency in Guwahati specializing in biological intelligence, generative AI, and regulatory systems for Asia's underrepresented populations.
Spearmint Resources Inc. is a Canadian mineral exploration company focused on lithium, gold, and antimony projects.
Eccoscience is a startup focused on developing AI-powered solutions for scientific research and discovery.
Feef is a voice-native AI agent that designs personalized fitness, nutrition, supplement, and recovery protocols, integrating them directly into your calendar.
Longevity and metabolic health platform offering personalized insights and interventions.
Discover innovative AI therapeutics at fibrotherapeutics.ai, enhancing patient care and advancing health technology.
An entrant is a company tagged Biotech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 2 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.